Mission

e-Therapeutics aims to discover new therapies systematically using its new complex systems-based discovery approaches, in order to alleviate treatable disease in as many areas as possible.

AIM rule 26 particulars

The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.

About e-Therapeutics

The following links contains information about the Company:  About Us

The following links contain information about our Directors including details of committees and their members: Board of Directors, Directors’ Responsibilities and Corporate Governance.

Country of Incorporation and Main Country of Operation

Country of Incorporation: England and Wales.

Company Number: 4304473.

Main Country of Operation: The head office and main operations are in Newcastle-upon-Tyne, England.

Current Constitutional Documents

The following links contain details of the constitutional documents for e-Therapeutics:

• Articles of Association
• Memorandum of Association

Details of Any Other Exchanges or Trading Platforms

The Company is not listed on any other exchanges or trading platforms.

Number of Securities in Issue

The Company’s share capital consists of an issued share capital of 65,420,292 ordinary shares in issue, with a nominal value of 0.1 pence each (”Ordinary Shares”), each share having equal voting rights. The company does not hold any Ordinary Shares in treasury. So far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 77.48%. At 11 November 2009, the following interests of shareholders in excess of 3% (significant shareholders), have been notified to the company:

Significant Shareholders and shareholdings

• Credit Suisse Client Nominees (UK) Limited is the nominee for RAB Special Situations (Master) Fund LLP- 16,357,950 (25.00%)

• Newcastle University Holdings Limited - 6,744,000 (10.31%)

• Octopus Group – 3,119,070 (4.77%)

• Pershing Nominees Limited – 3,180,108 (4.86%)

• Gartmore Investment Limited – 6,541,000 (9.998%)

• Malcolm Young - 20,620,482 (31.52%)

Details of any restrictions on the transfer of securities 

There are no restrictions on the transfer of securities.

Financial Reports

The annual reports, accounts, and interim results can be accessed as pdf documents via the following link: Reports and Accounts

Notifications, Admission Document and Circulars

All Stock Exchange Regulatory Announcements issued in the last 12 months may be accessed as pdf documents via the following links:

• Holdings in Company (11 November 2009)
• Placing with institutional investor (02 November 2009)
• Interim accounts 2009 (30 October 2009)
• Annual Report for the year ended 31 January 2009 (30 July 2009)
• Preliminary results for the year ended 31 January 2009 (27 July 2009)
• Director's Shareholding announcement (17 June 2009)
• Result of General Meeting (16 March 2009)
• Notice of General Meeting (25 February 2009)
• Notice of a General Meeting Proposed Placing of Ordinary Shares Proposed Issue of Warrants and Secured Loan Notes (25 February 2009)
• Announcement: 50% revenue share agreement for late-stage drug candidates (24 February 2009)
• e-Therapeutics partners with Cresset BioMolecular Discovery Ltd (26 January 2009)
• Positive Phase IIa clinical trial of antidepressant ETS6103 (14 January 2009)
• Patents granted for discovery technology in the USA (12 January 2009)
• Objective Capital Report on e-Therapeutics - Summary (19 November 2008)
• Objective Capital Report on e-Therapeutics - Full report (19 November 2008)
• Announcement: Driectors Dealings (31 October 2008)
• Positive Phase IIa clinical trial of oral asthma treatment (10 October 2008)
• Announcement: Partnership with KeyGen (15 September 2008)
• Announcement: Appointment of Brad Hoy (7 September 2008)
• Final results (21 July 2008)
• Directors/PDMR shareholding (4 April 2008)
• Holding(s) in Company (05 February 2008)
• Preclinical update (22 January 2008)
• Preclinical update (10 December 2007)
• Notification of Director's and Significant Shareholders' Interests (28 November 2007)
• First Day of Dealings Announcment (28 November 2007)
• Admission document (22 November 2007)
• Schedule 1 Announcement (22 November 2007)
• Intention to Float Announcement (8 October 2007)

Advisers

The following link has details of the Company’s Nominated Adviser and other key advisers: Advisers